JP2013522222A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522222A5
JP2013522222A5 JP2012557231A JP2012557231A JP2013522222A5 JP 2013522222 A5 JP2013522222 A5 JP 2013522222A5 JP 2012557231 A JP2012557231 A JP 2012557231A JP 2012557231 A JP2012557231 A JP 2012557231A JP 2013522222 A5 JP2013522222 A5 JP 2013522222A5
Authority
JP
Japan
Prior art keywords
monocyclic
optionally substituted
compound
hydrogen
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012557231A
Other languages
English (en)
Japanese (ja)
Other versions
JP5888654B2 (ja
JP2013522222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/027817 external-priority patent/WO2011112766A2/en
Publication of JP2013522222A publication Critical patent/JP2013522222A/ja
Publication of JP2013522222A5 publication Critical patent/JP2013522222A5/ja
Application granted granted Critical
Publication of JP5888654B2 publication Critical patent/JP5888654B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012557231A 2010-03-10 2011-03-10 疾患の治療のためのヒスタミン受容体の複素環阻害薬 Expired - Fee Related JP5888654B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31261510P 2010-03-10 2010-03-10
US61/312,615 2010-03-10
PCT/US2011/027817 WO2011112766A2 (en) 2010-03-10 2011-03-10 Heterocyclic inhibitors of histamine receptors for the treatment of disease

Publications (3)

Publication Number Publication Date
JP2013522222A JP2013522222A (ja) 2013-06-13
JP2013522222A5 true JP2013522222A5 (enExample) 2014-04-24
JP5888654B2 JP5888654B2 (ja) 2016-03-22

Family

ID=44564108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557231A Expired - Fee Related JP5888654B2 (ja) 2010-03-10 2011-03-10 疾患の治療のためのヒスタミン受容体の複素環阻害薬

Country Status (18)

Country Link
US (1) US8569300B2 (enExample)
EP (1) EP2545058B1 (enExample)
JP (1) JP5888654B2 (enExample)
KR (1) KR20130016253A (enExample)
CN (1) CN102869666B (enExample)
AR (1) AR080496A1 (enExample)
AU (1) AU2011224316B2 (enExample)
BR (1) BR112012022211A2 (enExample)
CA (1) CA2791417A1 (enExample)
ES (1) ES2607125T3 (enExample)
IL (1) IL221829A (enExample)
MX (1) MX2012010404A (enExample)
NZ (1) NZ602041A (enExample)
PH (1) PH12012501783A1 (enExample)
RU (1) RU2012137180A (enExample)
TW (1) TW201200518A (enExample)
UY (1) UY33271A (enExample)
WO (1) WO2011112766A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859550B2 (en) * 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
EP3290407B1 (en) 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
CA3021678A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物(二)
KR102515694B1 (ko) 2017-01-10 2023-03-29 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
BR112020007058A2 (pt) * 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) * 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
US11498930B2 (en) 2018-02-13 2022-11-15 Blueray Therapeutics (Shanghai) Co., Ltd Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
CN115448923B (zh) * 2018-02-13 2024-03-22 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
CN110655520A (zh) * 2018-06-29 2020-01-07 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
US12281118B2 (en) 2018-11-07 2025-04-22 Shanghai Ringene Biopharma Co., Ltd. Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP7357146B2 (ja) * 2019-08-22 2023-10-05 ブルーレイ セラピューティクス (シャンハイ) カンパニー,リミティド アザヘテロアリール化合物及びその使用
US12065444B2 (en) 2021-11-19 2024-08-20 Crossignal Therapeutics, Inc. Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929812A (en) * 1974-05-20 1975-12-30 Squibb & Sons Inc Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP1430898A4 (en) * 2001-09-28 2005-11-02 Kyowa Hakko Kogyo Kk Receptor antagonist
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
CN1310916C (zh) * 2002-06-25 2007-04-18 协和发酵工业株式会社 双环类杂环化合物
MXPA05002575A (es) 2002-09-06 2005-09-08 Johnson & Johnson Compuestos heterociclicos.
DK1753764T3 (da) * 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
WO2007063934A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
HRP20100378T1 (hr) * 2006-05-31 2010-08-31 Galapagos N.V. Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti
AU2007271187A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine H4 receptor
EP2066645A2 (en) 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
JP5769972B2 (ja) * 2008-02-08 2015-08-26 バジリア ファルマスーチカ アーゲーBasilea Pharmaceutica AG Pde阻害により仲介される疾患を処置するためのマクロライド
AR073739A1 (es) * 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
JP2012502067A (ja) * 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド 疾患の治療のためのヒスタミン受容体の複素環阻害剤
NZ596185A (en) * 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
WO2011019780A1 (en) * 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
PT3078664T (pt) 2009-12-17 2019-05-31 Boehringer Ingelheim Animal Health Usa Inc Composições antiparasitárias de di-hidroazoles
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
WO2011112687A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease

Similar Documents

Publication Publication Date Title
AU2011238616B2 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
IL221829A (en) Heterocyclic inhibitors of histamine receptors for the treatment of the disease
ES2673160T5 (es) Moduladores selectivos del receptor de la esfingosina 1 fosfato y métodos de síntesis quiral
KR102093608B1 (ko) 이미다조피리딘 화합물
ES2285784T3 (es) Derivados de pirazol.
JP2010506825A5 (enExample)
JPH11335375A (ja) ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
BRPI0616567A2 (pt) compostos ativadores da atividade de glicoquinases, composição farmacêutica, bem como o uso dos referidos compostos
WO2005115374A1 (en) Crth2 receptor ligands for therapeutic use
RU2019142795A (ru) Производное n-(азаарил)циклолактам-1-карбоксамида, метод его получения и его применение
JP2009533410A5 (enExample)
JP2017527578A5 (enExample)
RU2017135541A (ru) Гетероциклические амины и их применения
TW200524575A (en) Biaryl linked hydroxamates: preparation and pharmaceutical applications
JP2008513508A (ja) 炎症及び免疫に関連する用途に用いる化合物
JP2013531055A (ja) プロテインキナーゼIKKε及び/又はTBK−1の阻害剤としてのピリミジン化合物、それらの製造方法及びそれらを含む医薬組成物
JP4528918B2 (ja) カルボキサミド誘導体
JP2008504304A5 (enExample)
JP2009541404A5 (enExample)
RU2017112299A (ru) Способ получения ароматического гетероциклического соединения, применяемого в качестве селективного ингибитора киназы jak1, и применение ароматического гетероциклического соединения
WO2001058880A1 (en) Novel triazole derivatives
MXPA06014481A (es) Indazolcarboxamidas novedosas y su uso.
JP2011519845A5 (enExample)
CA2902431A1 (en) Halogenopyrazoles as inhibitors of thrombin
BR112015003824B1 (pt) Composto, composição farmacêutica e uso do composto